Hong Hur

Hong Hur

Auto-generated profile, based on publicly available information

Hong Hur

Department of Research Bioinformatics, Center for Clinical and Translational Science, The Rockefeller University Hospital, New York, NY, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2022 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
KNKristina Navrazhina
Kristina Navrazhina
JFJohn Frew
John Frew
DGDavid Grand
David Grand
SWSamuel C. Williams
Samuel C. Williams
HHHong Hur
Hong Hur
JKJames G. Krueger
James G. Krueger

18 December 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
BBBertrand Boisson
Bertrand Boisson
YHYoshitaka Honda
Yoshitaka Honda
MAMasahiko Ajiro
Masahiko Ajiro
JBJacinta Bustamante
Jacinta Bustamante
MBMatthieu Bendavid
Matthieu Bendavid
TYTakahiro Yasumi
Takahiro Yasumi
X-linked dominant incontinentia pigmenti (IP) and X-linked recessive anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) are caused by loss-of-function and hypomorphic IKBKG (also known as NEMO) mutations, respectively. We describe a European mother with mild IP and a Japanese mother without IP, whose 3 boys with EDA-ID died from ID. We identify the same private variant in an intron of IKBKG, IVS4+866 C>T, which was inherited from and occurred de novo in the European mother and Japanese mother, respectively. This mutation creates a new splicing donor site, giving rise to a 44-nucleotide pseudoexon (PE) generating a frameshift. Its leakiness accounts for NF-κB activation being impaired but not abolished in the boys’ cells. However, aberrant splicing rates differ between cell types, with WT NEMO mRNA and protein levels ranging from barely detectable in leukocytes to residual amounts in induced pluripotent stem cell–derived (iPSC-derived) macrophages, and higher levels in fibroblasts and iPSC-derived neuronal precursor cells. Finally, SRSF6 binds to the PE, facilitating its inclusion. Moreover, SRSF6 knockdown or CLK inhibition restores WT NEMO expression and function in mutant cells. A recurrent deep intronic splicing mutation in IKBKG underlies a purely quantitative NEMO defect in males that is most severe in leukocytes and can be rescued by the inhibition of SRSF6 or CLK.

20 January 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NTNatalia Teleshova
Natalia Teleshova
MKMarla J. Keller
Marla J. Keller
JRJosé A. Fernández Romero
José A. Fernández Romero
BFBarbara A. Friedland
Barbara A. Friedland
GCGeorge W. Creasy
George W. Creasy
TZThomas M. Zydowsky
Thomas M. Zydowsky
HIV pre-exposure prophylaxis (PrEP) is dominated by clinical therapeutic antiretroviral (ARV) drugs. Griffithsin (GRFT) is a non-ARV lectin with potent anti-HIV activity. GRFT’s preclinical safety, lack of systemic absorption after vaginal administration in animal studies, and lack of cross-resistance with existing ARV drugs prompted its development for topical HIV PrEP. We investigated safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of PC-6500 (0.1% GRFT in a carrageenan (CG) gel) in healthy women after vaginal administration. This randomized, placebo-controlled, parallel group, double-blind first-in-human phase 1 study enrolled healthy, HIV-negative, non-pregnant women aged 24–45 years. In the open label period, all participants (n = 7) received single dose of PC-6500. In the randomized period, participants (n = 13) were instructed to self-administer 14 doses of PC-6500 or its matching CG placebo (PC-535) once daily for 14 days. The primary outcomes were safety and PK after single dose, and then after 14 days of dosing. Exploratory outcomes were GRFT concentrations in cervicovaginal fluids, PD, inflammatory mediators and gene expression in ectocervical biopsies. This trial is registered with ClinicalTrials.gov, number NCT02875119. No significant adverse events were recorded in clinical or laboratory results or histopathological evaluations in cervicovaginal mucosa, and no anti-drug (GRFT) antibodies were detected in serum. No cervicovaginal proinflammatory responses and no changes in the ectocervical transcriptome were evident. Decreased levels of proinflammatory chemokines (CXCL8, CCL5 and CCL20) were observed. GRFT was not detected in plasma. GRFT and GRFT/CG in cervicovaginal lavage samples inhibited HIV and HPV, respectively, in vitro in a dose-dependent fashion. These data suggest GRFT formulated in a CG gel is a safe and promising on-demand multipurpose prevention technology product that warrants further investigation.

13 March 2026 in Science Advances
Verified
Journal Article
Open access
ECErin B. Cole
Erin B. Cole
SLSara Lamcaj
Sara Lamcaj
ASAgnes V. Sydenstricker
Agnes V. Sydenstricker
AVAdilyn G. Voss
Adilyn G. Voss
CHChristopher Hiner
Christopher Hiner
HGHarris Goldstein
Harris Goldstein
Functional persistence of chimeric antigen receptor T cells (CAR T cells) is limited by conventional CAR T cell manufacturing using anti-CD3/CD28 (αCD3/28) stimulation, which generates terminally differentiated and shorter-lived CAR T cells. We demonstrated that HCW9206, a unique protein scaffold linking interleukin-7 (IL-7), an IL-15/IL-15 receptor α (IL-15Rα) complex, and IL-21, generates CAR T cells without requiring αCD3/28 activation, which are highly enriched in long-lived T memory stem cells (T SCM cells) (>50%) and display potent activity across distinct disease models, HIV-1 or B cell leukemia. In a humanized mouse HIV infection model, HCW9206-generated anti-HIV duoCAR T cells suppressed viremia more effectively than αCD3/28-generated anti-HIV duoCAR T cells. In a xenograft leukemia mouse model, a recall proliferative response and complete clearance of leukemia rechallenge were displayed by HCW9206-generated but not by αCD3/28-generated anti-CD19 CAR T cells. HCW9206, a first-in-class cytokine scaffold–based platform, enables production of more potent CAR T cell–based immunotherapies by generating a CAR T cell population, which is highly functional and also markedly enriched for long-lived T SCM cells. This strategy is broadly applicable to increase persistence and functionality of CAR T cells, enhancing their efficacy for treating infectious disease and cancer.


6 August 2021 in Allergy
Verified
Journal Article
Closed access
PDF file
MMMika Murai‐Yamamura
Mika Murai‐Yamamura
SGSandra Garcet
Sandra Garcet
KYKazuhiko Yamamura
Kazuhiko Yamamura
JGJuana Gonzalez
Juana Gonzalez
SMShunsuke Miura
Shunsuke Miura
JKJames G. Krueger
James G. Krueger